Publicacións nas que colabora con Magdalena Salcedo Plaza (21)

2024

  1. Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study

    Annals of Hepatology, Vol. 29, Núm. 3

2023

  1. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration

    Hepatology, Vol. 77, Núm. 4, pp. 1095-1105

2022

  1. Decreased Long-Term Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019

    Liver Transplantation, Vol. 28, Núm. 6, pp. 1039-1050

  2. Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 6, pp. 335-342

  3. Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study

    Liver Transplantation, Vol. 28, Núm. 7, pp. 1257-1261

2021

  1. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients

    American Journal of Transplantation, Vol. 21, Núm. 8, pp. 2876-2884

  2. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients

    Journal of Hepatology, Vol. 74, Núm. 1, pp. 148-155

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

  2. Influence of donor liver CYP3A4∗20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients

    Pharmacogenetics and Genomics, Vol. 28, Núm. 2, pp. 41-48

  3. Prevalence and progression of chronic kidney disease after liver transplant: a prospective, real-life, observational, two-year multicenter study

    Revista Española de Enfermedades Digestivas, Vol. 110, Núm. 9, pp. 538-543

2017

  1. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study

    Transplant International, Vol. 30, Núm. 10, pp. 1041-1050

  2. Recommendations of everolimus use in liver transplant

    Gastroenterologia y Hepatologia

  3. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

    Hepatology, Vol. 65, Núm. 6, pp. 1810-1822

2016

  1. Erratum: Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study (Journal of Hepatology (2015) 62 (92-100))

    Journal of Hepatology

  2. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2015

  1. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study

    Journal of Hepatology, Vol. 62, Núm. 1, pp. 92-100

  2. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain

    Liver Transplantation, Vol. 21, Núm. 8, pp. 1056-1065

  3. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante

    Cirugia Espanola, Vol. 93, Núm. 10, pp. 619-637

2013

  1. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in caucasian spanish liver transplant patients

    Journal of Clinical Pharmacology, Vol. 53, Núm. 11, pp. 1146-1154

2012

  1. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation

    Liver Transplantation, Vol. 18, Núm. 1, pp. 45-52